+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer



Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer



Journal for ImmunoTherapy of Cancer 7(1): 24



Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 2018 were enrolled in this study. PD-L1 expression in tumor cells (TC) and mismatch repair (MMR) were analyzed by immunohistochemistry. Epstein-Barr virus (EBV) was detected by in situ hybridization. Cancer genome alterations were evaluated by a next-generation sequencing-based panel. High tumor mutation burden (TMB) was defined as more than 10 mutations/megabase. A total of 80 pts were analyzed in this study. Tumor response was evaluated in 72 pts with measurable lesions and 14 pts (19%) had an objective response. Overall response rate (ORR) was significantly higher in pts with ECOGPS 0 in those with PS 1 or 2, MMR-deficient (MMR-D) in those with MMR-proficient (MMR-P), PD-L1+ in TC in those with PD-L1- in TC and PIK3CA mutation in those with PIK3CA wild-type. ORR was 31% in pts with at least one of the following factors; MMR-D, high TMB, EBV+ and PD-L1+ in TC vs. 0% in those without these factors. Progression-free survival was significantly longer in pts with PS 0 than in those with PS 1 or 2, MMR-D than in those with MMR-P, and PD-L1+ in TC than in those with PD-L1- in TC. Some features were associated with favorable response to nivolumab for AGC. Combining these features might be useful to predict efficacy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446607

Download citation: RISBibTeXText

PMID: 30704511

DOI: 10.1186/s40425-019-0514-3


Related references

Analysis of clinicopathological features and prognosis in patients with advanced gastric cancer in different locations. Zhonghua Wei Chang Wai Ke Za Zhi 18(12): 1248-1252, 2016

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investigational New Drugs 35(4): 529-536, 2017

Study on endoscopic features in responders to systemic chemotherapy in advanced gastric cancer. Nihon Gan Chiryo Gakkai Shi 25(10): 2519-2525, 1990

Clinicopathological features of advanced gastric cancer. Report on 400 operated cases. Il Giornale di Chirurgia 20(3): 87-93, 1999

Clinicopathological features of advanced gastric cancer detected by periodic mass screening. Surgery Today (Tokyo) 22(2): 120-123, 1992

Clinicopathological Features and Survival of Patients with Gastric Cancer with a Family History: a Large Analysis of 2,736 Patients with Gastric Cancer. Journal of Gastric Cancer 17(2): 162-172, 2017

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer 2019, 2019

Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. Journal of Gastric Cancer 11(2): 69-77, 2011

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. Bmc Research Notes 7: 271, 2015

Study on the different expression of molecular markers between cardiac cancer and distal gastric cancer and their correlations with clinicopathological features. Digestive Surgery 26(5): 384-391, 2010

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecologic Oncology Reports 24: 1-5, 2018

Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. European Journal of Gastroenterology and Hepatology 17(12): 1345-1349, 2005

The differences in clinicopathological features and prognosis among the subtypes of signet ring cell, mucinous, papillary, and lymphoepithelioma-like carcinoma in advanced gastric cancer. Hepato-Gastroenterology 61(135): 2149-2155, 2015

Clinicopathological features of gastric cancer in young patients. Gastric Cancer 19(2): 472-478, 2016

Clinicopathological features of patients who died with second primary cancer after curative resection for gastric cancer. Anticancer Research 15(3): 1049-1053, 1995